What is PharmaJet?
PharmaJet operates at the intersection of medical device innovation and public health infrastructure. The company is dedicated to the global adoption of its proprietary needle-free injection technology, positioning its devices as the new standard of care for vaccine administration. By effectively mitigating the risks associated with traditional sharps—including needle-stick injuries, cross-contamination, and the logistical burden of medical waste disposal—PharmaJet provides a high-efficiency solution for healthcare providers. Their technology is engineered to be fast, safe, and user-friendly, addressing systemic challenges in immunization programs and clinical settings worldwide. As the market for non-invasive medical delivery systems matures, PharmaJet remains a key player in driving the transition toward safer, more sustainable clinical practices.
How much funding has PharmaJet raised?
PharmaJet has raised a total of $38.7M across 10 funding rounds:
Unspecified
$9.1M
Unspecified
$4.2M
Unspecified
$3.4M
Unspecified
$2.8M
Unspecified
$2.2M
Unspecified
$2.5M
Unspecified
$5.2M
Private Equity
$6M
Private Equity
$3M
Debt
$283K
Unspecified (2009): $9.1M, investors not publicly disclosed
Unspecified (2011): $4.2M, investors not publicly disclosed
Unspecified (2011): $3.4M, investors not publicly disclosed
Unspecified (2012): $2.8M, investors not publicly disclosed
Unspecified (2012): $2.2M, investors not publicly disclosed
Unspecified (2013): $2.5M, investors not publicly disclosed
Unspecified (2013): $5.2M, investors not publicly disclosed
Private Equity (2015): $6M, investors not publicly disclosed
Private Equity (2017): $3M, investors not publicly disclosed
Debt (2021): $283K backed by PPP
Key Investors in PharmaJet
PPP
Public-Private Partnership
Undisclosed Investor
A private equity firm specializing in late-stage medical technology investments and enterprise-level scaling.
Undisclosed Investor
An institutional backer focused on long-term growth within the healthcare and medical device manufacturing sectors.
What's next for PharmaJet?
With the recent capital injection, PharmaJet is well-positioned to accelerate its market penetration and refine its manufacturing capabilities to meet rising global demand. The strategic focus will likely shift toward expanding clinical partnerships and enhancing the scalability of its needle-free platforms. By leveraging this financial backing, the company aims to solidify its competitive advantage in the vaccine delivery market, potentially exploring new therapeutic applications for its injection technology. As the firm moves into this next phase of development, the emphasis will remain on operational excellence and the continued validation of its devices as a primary alternative to conventional needle-based delivery methods, ensuring long-term value creation for stakeholders and improved safety outcomes for patients globally.
See full PharmaJet company page
